ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
52 announcements with these filters
Dishman Carbogen Amcis paid ₹1.26 Crore in quarterly interest for NCDs. Payment was completed on June 26, 2026.
Subsidiary Carbogen Amcis AG commissioned a 1,200 kWp solar plant in Switzerland. This project supports the company's commitment to sustainability and renewable energy.
Dishman Carbogen Amcis Limited allotted 1,800 Non-Convertible Debentures (NCDs) aggregating to ₹18 Crore. These secured instruments mature on December 9, 2027.
Dishman Carbogen Amcis Limited fixed June 30, 2026, as the record date for NCD interest and redemption payments. Payments for these 4,999 debentures are due on July 15, 2026.
Dishman Carbogen Amcis submitted its Annual Secretarial Compliance Report for FY2026. The report by Ashok P. Pathak & Co. confirms general regulatory compliance with minor procedural observations.
Dishman Carbogen Amcis convened an EGM to approve a ₹2,452 Crore loan from promoter group entity Aamanya AG. The ten-year facility supports increased borrowing limits.
Dishman Carbogen Amcis called an EGM on June 19, 2026, to approve increasing borrowing limits to ₹4,000 Crore. Shareholders will also vote on a ₹1,850 Crore promoter loan.
Dishman Carbogen Amcis scheduled an EGM for June 19, 2026, via video conferencing. Shareholders will vote on increasing borrowing limits and related party transactions.
Dishman Carbogen Amcis reported Q4 FY26 revenue of ₹851cr (up 19% YoY) and EBITDA of ₹163cr. Strategy focuses on high-margin ADC products and India site tech transfers.
Dishman Carbogen Amcis reported strong FY26 performance with revenue up 8.1% and EBITDA margins expanding to 19.3%. Growth is driven by CDMO and Vitamin D analogue segments.
Dishman Carbogen Amcis Ltd reported revenue from operations of ₹851.4 Cr (+18.9% YoY) and net profit of ₹21.7 Cr (-49.7% YoY) for Q4 FY26.
Dishman Carbogen Amcis approved audited results and increased borrowing limits to ₹4,000 Crore. The board also authorized availing ₹2,452 Crore in external commercial borrowings.
Dishman Carbogen Amcis scheduled a board meeting for May 19, 2026. Key agenda items include approving annual results and a ₹1282.50 Crore promoter-group loan.
Dishman Carbogen Amcis' wholly-owned subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., successfully completed an unannounced GMP inspection by China's NMPA on April 14, 2026. The inspection of the Shanghai API facility concluded with no observations. This confirms the site's compliance with international regulatory standards and supports the company's growth in China.
Dishman Carbogen Amcis Ltd paid ₹3.09 Crore towards interest and partial redemption of NCDs (ISIN: INE385W07034) on April 28, 2026. The payment followed a put option exercise by debenture holders for 300 units.
Dishman Carbogen Amcis Ltd paid ₹1.23 Crore in interest and redeemed ₹4.17 Crore in principal for its NCDs (ISIN: INE385W07059) on April 18, 2026. The total payment of ₹5.40 Crore represents the first quarterly obligation for the secured, rated NCDs, with a post-redemption outstanding face value of ₹91,666.67 per unit.
Dishman Carbogen Amcis Limited has appointed Mr. Sandeep Jaiswal as Vice President - International Marketing, effective April 20, 2026. Mr. Jaiswal brings 27 years of experience in API and specialty chemicals marketing, previously serving at Apotex Pharmachem India. This appointment strengthens the company's senior leadership and international business development capabilities.
Dishman Carbogen Amcis Limited appointed Mr. Sandeep Jaiswal as Vice President - International Marketing, effective April 20, 2026. Mr. Jaiswal brings 27 years of experience in API and specialty chemicals marketing, previously serving at Apotex Pharmachem India. This strategic hire aims to strengthen the company's international business development and marketing leadership.
Dishman Carbogen Amcis Limited has appointed Mr. Sandeep Jaiswal as Vice President (International Marketing) effective April 20, 2026. Mr. Jaiswal brings 27 years of experience in the pharmaceuticals and chemicals sectors, previously serving as General Manager – Marketing at Apotex Pharmachem India.
Dishman Carbogen Amcis Limited submitted its annual disclosure for Non-Convertible Debentures (NCDs) for the period ended March 31, 2026. The filing includes listing details, hyperlinks to exchange notifications, and current credit ratings from India Ratings & Research. The company confirmed that all interest and redemption payments due up to the period end were successfully made.
Dishman Carbogen Amcis Limited submitted its half-yearly statement of private placement of debt securities for the period ended March 31, 2026. The company reported three outstanding NCD series with a total outstanding value of ₹135.38 Crore. This filing ensures regulatory compliance regarding its non-convertible debenture obligations.
Dishman Carbogen Amcis Ltd has fixed April 15, 2026, as the record date for interest payment and partial redemption of 300 NCD units (ISIN: INE385W07034). The payment is scheduled for April 30, 2026, following the exercise of a put option by certain debenture holders.